Lourdes sells AGN 279.03: BMO Capital Markets set a $378.00 price target on shares of Allergan and gave the stock a buy rating in a research note on Saturday, June 20th.

JPMorgan Chase & Co. reaffirmed a buy rating on shares of Allergan in a research note on Tuesday, September 15th. A number of other research firms have also commented on AGN. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Absent the approval of a low cost biosimilars such as Amgen and Allergan's ABP 215, demand for NSCLC therapy could have a big negative impact on healthcare spending. Unfortunately, non-small-cell lung cancer is the leading cause of cancer death in both men and women and in the U.S. and EU, a combined half a million new cases of the cancer are diagnosed every year.


Bonny:
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.

Tonda:
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Sara:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Roseann:
Outdoor air pollution and lung cancer: recent epidemiologic evidence.

Magdalen:
Lung cancer risk from residential radon: meta-analysis of eight epidemiologic studies.

Lidia:
Systematic review of the relationship between family history and lung cancer risk.

Chang:
The accumulated evidence on lung cancer and environmental tobacco smoke.

Mark:
Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

Kimber:
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S.

Pura:
If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions.

Allergan (NYSE:AGN)
//stockhand.net/us/?q=nyse%3Aagn&id=589282